Search

everythinglearnresearchcommunity

for

Search:↓

Men with early hair loss may have a higher risk of enlarged prostate and possibly prostate cancer due to shared hormonal factors.

Treatment for benign prostatic hyperplasia involves drugs that either quickly relieve symptoms or reduce prostate size, with a combination offering more benefits but more side effects.

Saw palmetto extract can block the enzyme that converts testosterone in pig prostate cells.

NcoA4 may have roles beyond helping control gene activity, possibly affecting cell behavior and stability.

5-alpha-reductase inhibitors help treat urinary symptoms from an enlarged prostate.

Early hair loss in men could be a sign of non-cancerous prostate enlargement, and treating hair loss early might help prevent prostate issues later.

FGF5 gene mutations cause long hair in domestic cats.

Hair loss can be an early sign of prostate enlargement.

Ezetimibe effectively reduces prostate size in cases of benign prostatic hyperplasia.

Men with male pattern baldness have a higher risk of aggressive prostate cancer and benign prostatic hyperplasia.

Prostate cancer patients need early psychological and sexual support during radiotherapy to improve their quality of life.

A higher genetic risk score increases the chance of getting benign prostatic hyperplasia and affects treatment outcomes in Han Chinese men.

Trapa bispinosa Roxb. extract may help reduce prostate size and cell growth in BPH.

Androgen receptors are active in many tissues of both male and female mice, not just reproductive organs.

Treatments for enlarged prostate can cause problems with ejaculation, and less invasive options might preserve sexual function better.

5-alpha reductase inhibitors, like finasteride and dutasteride, are used for prostate issues, hair loss, and excessive hair growth, may help with COVID-19, but can cause sexual and mental health side effects, and their use in preventing prostate cancer needs more examination.

Scientists made the first metal-based compounds from a nonsteroidal antiandrogen drug, which showed potential in fighting both hormone-dependent and independent prostate cancer cells.

The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.

5α-reductase is essential for male sexual development and its inhibitors have potential in treating various conditions related to hormone action.

Antiandrogens affect androgen-dependent body functions and are used for various medical conditions, with some risks like fetus feminization, but new forms like 17α-propylmesterolone show promise for acne without systemic effects.

New sulfur-containing steroid analogs show promise for more targeted medical treatments.

Some diseases can improve the outcomes of other diseases, leading to new treatment possibilities.

FCE 28260 is a stronger and longer-lasting inhibitor of 5α-reductase than finasteride, which may make it a better treatment for certain medical conditions.

Androgens and SARMs play a role in body mass, frailty, skin health, and hair growth, and are used in treating prostate cancer, acne, and hair loss, with potential for new uses and improved versions in the future.

Finasteride may help prevent chronic bacterial prostatitis, with better results when combined with antibiotics.

Adding cerium(III) chloride to Grignard reagents improves the making of compounds that could treat prostate issues and hair loss.

Dutasteride works better than finasteride for preventing and treating prostate cancer.

Finasteride may reduce bleeding after TURP, but more research needed.

Doctors should prescribe cheaper, off-label medication and teach patients how to use it to save money ethically.

The body's change of testosterone into DHT is not necessary for testosterone's muscle and sexual effects.